Reported Earnings • Jul 02
Full year 2026 earnings released: UK£0.006 loss per share (vs UK£0.017 loss in FY 2025) Full year 2026 results: UK£0.006 loss per share (improved from UK£0.017 loss in FY 2025). Net loss: UK£425.0k (loss narrowed 61% from FY 2025). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Jul 01
Truetide plc, Annual General Meeting, Jul 24, 2026 Truetide plc, Annual General Meeting, Jul 24, 2026. Location: unit 2, common farm, common lane, mappleborough green, warwickshire, b80 7dp, United Kingdom New Risk • Jun 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 68% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£2.43m market cap, or US$3.25m). Minor Risk Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). New Risk • May 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 68% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£2.16m market cap, or US$2.89m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). New Risk • Jan 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 68% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£2.08m market cap, or US$2.80m). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Shareholders have been diluted in the past year (23% increase in shares outstanding). Tillkännagivande • Dec 16
Susan Hagan to Step Down from the Board as Non-Executive Director of Truetide plc, Effective 31 December 2025 Truetide plc announced that Dr. Susan Hagan will step down from the Board as Non-Executive Director with effect from 31 December 2025. Reported Earnings • Oct 29
First half 2026 earnings released: EPS: UK£0.002 (vs UK£0.001 in 1H 2025) First half 2026 results: EPS: UK£0.002 (up from UK£0.001 in 1H 2025). Net income: UK£129.0k (up 196% from 1H 2025). Over the last 3 years on average, earnings per share has fallen by 38% per year whereas the company’s share price has fallen by 36% per year. Tillkännagivande • Oct 15
Imaging Biometrics Ltd. (LSE:IBAI) entered into share purchase agreement to acquire 86.11% stake in Kirkstall Limited from Truetide plc (AIM:TRUE) for £0.17 million. Imaging Biometrics Ltd. (LSE:IBAI) entered into share purchase agreement to acquire 86.11% stake in Kirkstall Limited from Truetide plc (AIM:TRUE) for £0.17 million on October 10, 2025. The total consideration for the sale is £0.14 million equivalent to £0.015 per Kirkstall share, and will be satisfied by the issuance of an unsecured Convertible Loan Note by IBAI to Truetide. The Convertible Loan Note has a principal value of £0.17 million of £0.14 million which will be subscribed for by Truetide in settlement of the Consideration and £0.02 million will be subscribed for in cash. The Convertible Loan Note bears interest at 6% per annum, which will accrue and be added to the loan balance. It is unsecured and subordinated, and may be converted into Ordinary Shares of IBAI at the discretion of Truetide, in whole or in part, at the lower of £0.075 or the subscription price of any fundraising completed by IBAI prior to conversion. The final redemption date is 31 December 2027. Following completion of the sale, Kirkstall's shareholder agreement includes drag-along provisions that would enable IBAI to acquire the remaining shares in Kirkstall not covered by the SPA. It is anticipated that IBAI will exercise these provisions to acquire 100% ownership of Kirkstall.
James Reeve of Allenby Capital Limited acted as financial advisor to Truetide plc. Tillkännagivande • Jul 10
Braveheart Investment Group plc, Annual General Meeting, Aug 01, 2025 Braveheart Investment Group plc, Annual General Meeting, Aug 01, 2025. Location: unit 2, common farm, common lane, mappleborough green, warwickshire, b80 7dp, United Kingdom Reported Earnings • Jul 10
Full year 2025 earnings released: UK£0.017 loss per share (vs UK£0.11 loss in FY 2024) Full year 2025 results: UK£0.017 loss per share (improved from UK£0.11 loss in FY 2024). Net loss: UK£1.09m (loss narrowed 85% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 38 percentage points per year, which is a significant difference in performance. New Risk • May 22
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 23% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£1.80m market cap, or US$2.42m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Shareholders have been diluted in the past year (23% increase in shares outstanding). Tillkännagivande • May 22
Braveheart Investment Group plc has completed a Follow-on Equity Offering in the amount of £0.295 million. Braveheart Investment Group plc has completed a Follow-on Equity Offering in the amount of £0.295 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,750,000
Price\Range: £0.02
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,000,000
Price\Range: £0.02
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 5,630,000
Price\Range: £0.02
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,370,000
Price\Range: £0.02
Transaction Features: Subsequent Direct Listing New Risk • May 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£1.43m market cap, or US$1.90m). Minor Risk Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Tillkännagivande • May 16
Braveheart Investment Group plc has completed a Follow-on Equity Offering in the amount of £0.195 million. Braveheart Investment Group plc has completed a Follow-on Equity Offering in the amount of £0.195 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,750,000
Price\Range: £0.02
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,000,000
Price\Range: £0.02
Transaction Features: Subsequent Direct Listing New Risk • May 04
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£2.39m market cap, or US$3.17m). Minor Risk Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£2.55m market cap, or US$3.24m). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change). Buy Or Sell Opportunity • Apr 03
Now 26% undervalued after recent price drop Over the last 90 days, the stock has fallen 11% to UK£0.043. The fair value is estimated to be UK£0.057, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 107% over the last 3 years. Meanwhile, the company became loss making. Tillkännagivande • Mar 19
Braveheart Investment Group plc has filed a Follow-on Equity Offering in the amount of £0.25 million. Braveheart Investment Group plc has filed a Follow-on Equity Offering in the amount of £0.25 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 25,000,000
Price\Range: £0.01
Transaction Features: Subsequent Direct Listing New Risk • Nov 28
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 42% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£2.71m market cap, or US$3.44m). Recent Insider Transactions • Nov 10
CEO & Non-Executive Director recently bought UK£91k worth of stock On the 7th of November, Trevor Brown bought around 3m shares on-market at roughly UK£0.035 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Trevor's only on-market trade for the last 12 months. Reported Earnings • Oct 15
First half 2025 earnings released: EPS: UK£0.001 (vs UK£0.011 loss in 1H 2024) First half 2025 results: EPS: UK£0.001 (up from UK£0.011 loss in 1H 2024). Net income: UK£43.6k (up UK£775.8k from 1H 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Tillkännagivande • Oct 11
Braveheart Investment Group plc (AIM:BRH) acquired 29.51% stake in IQ-AI Limited (LSE:IQAI) from Trevor Brown and Free Association Books Limited for £0.719 million. Braveheart Investment Group plc (AIM:BRH) acquired 29.51% stake in IQ-AI Limited (LSE:IQAI) from Trevor Brown and Free Association Books Limited for £0.719 million on October 11, 2024. 45,761,083 shares in IQ-AI have been purchased from Trevor Brown, CEO of Braveheart, at a price of 1.1 pence per share, for a consideration of £0.503 million. A further 19,654,779 shares in IQ-AI Shares have been purchased from Free Association Books Limited, a company owned by the children of Trevor Brown, also at a price of 1.1p per IQ-AI share for a consideration of £0.216 million. In the year ended 31 December 2023, IQ-AI made a loss before tax of approximately £0.62 million on revenue of approximately £0.6 million and as at that date had net assets of approximately £0.09 million. Allenby Capital Limited acted as financial advisor for Braveheart Investment Group plc.
Braveheart Investment Group plc (AIM:BRH) completed the acquisition of 29.51% stake in IQ-AI Limited (LSE:IQAI) from Trevor Brown and Free Association Books Limited on October 11, 2024. Tillkännagivande • Aug 01
Braveheart Investment Group plc (AIM:BRH) acquired an additional 15% stake in Gyrometric Systems Limited for £0.0225 million. Braveheart Investment Group plc (AIM:BRH) acquired an additional 15% stake in Gyrometric Systems Limited for £0.0225 million on July 9, 2024. James Reeve and George Payne of Allenby Capital Limited act as financial advisor for Braveheart Investment Group plc (AIM:BRH).
Braveheart Investment Group plc (AIM:BRH) completed the acquisition of an additional 15% stake in Gyrometric Systems Limited on July 9, 2024. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Independent Non-Executive Director Qu Li was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jun 23
Full year 2024 earnings released: UK£0.11 loss per share (vs UK£0.027 profit in FY 2023) Full year 2024 results: UK£0.11 loss per share (down from UK£0.027 profit in FY 2023). Net loss: UK£7.25m (down UK£8.83m from profit in FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. Tillkännagivande • Jun 22
Braveheart Investment Group plc, Annual General Meeting, Jul 18, 2024 Braveheart Investment Group plc, Annual General Meeting, Jul 18, 2024. Location: the office of china ventures ltd, unit 2, common farm, common lane, warwickshire, b80 7dp, mappleborough green United Kingdom Tillkännagivande • Mar 05
Bruker Uk Limited completed the acquisition of Phasefocus Holdings Limited from Braveheart Investment Group plc (AIM:BRH) and other shareholders. Bruker Uk Limited entered into a conditional sale and purchase agreement to acquire Phasefocus Holdings Limited from Braveheart Investment Group plc (AIM:BRH) and other shareholders for £5 million on December 21, 2023. The total consideration for the Sale will be payable in cash, subject to customary adjustments for working capital, cash, debt and transaction costs. Completion of the Sale is subject to customary closing conditions being satisfied and the granting of probate relating to a deceased Phasefocus Shareholder and is therefore expected to take place in Q1 2024. James Reeve and George Payne of acted as financial advisor to Braveheart Investment Group plc.
Bruker Uk Limited completed the acquisition of Phasefocus Holdings Limited from Braveheart Investment Group plc (AIM:BRH) and other shareholders on Marc h 4, 2024. Tillkännagivande • Dec 23
Bruker Uk Limited entered into a conditional sale and purchase agreement to acquire Phasefocus Holdings Limited from Braveheart Investment Group plc (AIM:BRH) and other shareholders for £5 million. Bruker Uk Limited entered into a conditional sale and purchase agreement to acquire Phasefocus Holdings Limited from Braveheart Investment Group plc (AIM:BRH) and other shareholders for £5 million on December 21, 2023. The total consideration for the Sale will be payable in cash, subject to customary adjustments for working capital, cash, debt and transaction costs. Completion of the Sale is subject to customary closing conditions being satisfied and the granting of probate relating to a deceased Phasefocus Shareholder and is therefore expected to take place in Q1 2024. James Reeve and George Payne of acted as financial advisor to Braveheart Investment Group plc. Reported Earnings • Dec 16
First half 2024 earnings released: UK£0.011 loss per share (vs UK£0.01 loss in 1H 2023) First half 2024 results: UK£0.011 loss per share (further deteriorated from UK£0.01 loss in 1H 2023). Net loss: UK£732.2k (loss widened 30% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance. New Risk • Oct 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (31% accrual ratio). Market cap is less than US$10m (UK£7.01m market cap, or US$8.62m). Minor Risks Share price has been volatile over the past 3 months (7.4% average weekly change). Revenue is less than US$5m (UK£3.2m revenue, or US$3.9m). New Risk • Aug 20
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.81m (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (31% accrual ratio). Market cap is less than US$10m (UK£7.81m market cap, or US$9.94m). Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (UK£3.2m revenue, or US$4.0m). Tillkännagivande • Jul 06
Braveheart Investment Group plc, Annual General Meeting, Jul 28, 2023 Braveheart Investment Group plc, Annual General Meeting, Jul 28, 2023, at 09:30 Coordinated Universal Time. Location: the office of China Ventures Ltd, Unit 2, Common Farm, Common Lane, Mappleborough Green, Warwickshire United Kingdom Reported Earnings • Jul 04
Full year 2023 earnings released: EPS: UK£0.027 (vs UK£0.031 in FY 2022) Full year 2023 results: EPS: UK£0.027. Revenue: UK£3.18m (up 8.3% from FY 2022). Net income: UK£1.58m (up 9.0% from FY 2022). Profit margin: 50% (in line with FY 2022). Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Qu Li was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 28
First half 2023 earnings released: UK£0.012 loss per share (vs UK£0.049 profit in 1H 2022) First half 2023 results: UK£0.012 loss per share (down from UK£0.049 profit in 1H 2022). Net loss: UK£767.1k (down 130% from profit in 1H 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Tillkännagivande • Aug 05
Braveheart Investment Group plc (AIM:BRH) agreed to acquire a 7.89% stake in Aukett Swanke Group Plc (AIM : AUK) from Trevor Brown for £0.22 million. Braveheart Investment Group plc (AIM:BRH) agreed to acquire a 7.89% stake in Aukett Swanke Group Plc (AIM : AUK) from Trevor Brown for £0.22 million on August 3, 2022. The consideration will be satisfied by the issue of a total of 1,991,651 shares in Bravehear. Upon completion of the transaction, Braveheart will own 7.89 per cent. of the issued share capital of ASG and Trevor Brown will no longer have a holding of ordinary shares in ASG. David Worlidge, James Reeve and George Payne of Allenby Capital Limited acted as financial advisor of Bravehear. Tillkännagivande • Jul 21
Braveheart Investment Group plc Provides the Update on Paraytec Braveheart Investment Group plc provided the following update on Paraytec. The clinical study at the Sheffield Teaching Hospital NHS Trust, referred to in the RNS of 16 June 2022, is in the final setup phase at the hospital, with recruitment expected to start within the next two weeks. This study will run alongside the Trust's existing NHS drive-through COVID-19 testing service for staff. In the first phase, up to 100 participants, 50 of whom are positive for COVID-19 and 50 who are negative, will provide swab specimens for analysis by Paraytec's CX300 instrument. This data will be compared to separate analyses by polymerase chain reaction (PCR) and for some samples, culture for live SARS-CoV-2 virus in the laboratory. Culturing virus samples gives a reference standard for whether the participant is likely to be transmitting virus and will be performed by Professor Carl Smythe's team in a Containment level 3 laboratory (CAT3) at Sheffield University's Medical School. This study is expected to last around 4 weeks and, subject to its performance, will be followed by a longitudinal study to monitor the course of infection of participants over a ten-day period. The sepsis test project continues to make progress. The target surface proteins in Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus (which represent over 50% of cases of bacteraemia in the local population) have been identified, along with suitable unique candidate antibodiess which will be used to attach fluorophore markers. The next stage will be to test these assays in the CAT3 laboratory. In parallel, the first multiwavelength CX300 instrument is being built and these will be brought together to formally demonstrate Proof of Concept. The analysis of Virus Like Particles (VLPs) is a further application of Paraytec's technology. VLP's are a key technology used to deliver treatments in the rapidly growing market for gene therapy medicine. These VLPs are capsids (very small biological capsules) and are used to carry a modified DNA that will perform the gene therapy, into a patient's body. Critical to patient safety is the quality control of these VLPs. However, current analytical methods are not well suited to testing these materials during all the stages of VLP manufacture. Paraytec is now building a modified CX300 instrument to show that its new technology can be used to detect the ratio of full/empty capsids, a critical quality attribute to be determined both during production and following purification. Paraytec is working with FUJIFILM Diosynth Biotechnologies and the UK's Cell and Gene Therapy Catapult on a collaborative proposal for development of instrumentation and comparing performance with current analytical methods during manufacturing runs. Reported Earnings • Jun 17
Full year 2022 earnings released: EPS: UK£0.031 (vs UK£0.37 in FY 2021) Full year 2022 results: EPS: UK£0.031 (down from UK£0.37 in FY 2021). Revenue: UK£2.94m (down 62% from FY 2021). Net income: UK£1.45m (down 90% from FY 2021). Profit margin: 50% (down from 184% in FY 2021). The decrease in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 88% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Qu Li was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Mar 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Qu Li was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 20
First half 2022 earnings released: EPS UK£0.049 (vs UK£0.013 in 1H 2021) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2022 results: Revenue: UK£3.36m (up 276% from 1H 2021). Net income: UK£2.54m (up 445% from 1H 2021). Profit margin: 76% (up from 52% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Aug 06
Braveheart Investment Group plc Announces Further Update re Paraytec AD Scanner Project Braveheart Investment Group plc regarding Paraytec's work with partners in the field of Alzheimer's disease detection and also the Covid-19 detection project. Prototype instruments were shipped to project partners in early July 2021 and sample testing has commenced. The initial results from Vrije University Medical Centre Amsterdam using AD patient samples were inconclusive. The cause and implications of these initial results are not yet known. Further testing is needed and although the funded project will end at the end of this month, Paraytec's partners have indicated that they will continue the testing thereafter. A further update is expected by the end of September 2021. Paraytec's work to develop an instrument for the detection of COVID-19 is progressing as planned and a corporate finance specialist has been engaged to market the technology to potential partners or acquirers. The company anticipates releasing the next update for both the COVID-19 and AD scanner projects will be around the end of September 2021. Recent Insider Transactions • Jul 01
CEO & Director recently sold UK£556k worth of stock On the 29th of June, Trevor Brown sold around 1m shares on-market at roughly UK£0.42 per share. In the last 3 months, they made an even bigger sale worth UK£827k. Trevor has been a seller over the last 12 months, reducing personal holdings by UK£4.2m. Reported Earnings • Jun 20
Full year 2021 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£16.6m (up UK£16.3m from FY 2020). Net income: UK£14.0m (up UK£14.6m from FY 2020). Profit margin: 85% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Tillkännagivande • Jun 15
Braveheart Investment Group plc Updates on the Paraytec AD Scanner Project Braveheart Investment Group plc Updated on the Paraytec AD Scanner project. Paraytec's grant funded project to deploy its ActiPix technology in the field of Alzheimer's disease (AD) diagnosis, working with a pan-European consortium of Karolinska Institute, Biomotif, Vrije University Medical Centre Amsterdam (VUMC) and MS Vision is progressing well. Prototype instruments are being built, to test blood for protein biomarkers. If successful, these instruments will be used by clinicians aiming to more accurately diagnose patients and monitor their treatment. Pooled plasma samples from AD patients and healthy individuals have been tested in the laboratory and produced good results. In the next month, VUMC will begin testing the system with plasma samples from individual AD patients, to assess the pre-clinical performance and correlation with clinical diagnosis. The first fully assembled instrument, incorporating Paraytec's detector technology, has been produced by MS Vision and shipped to Karolinska Institute in Sweden for testing. The instrument uses capillary isoelectric focusing (cIEF), together with ActiPix technology, to measure the level of protein biomarkers (abnormal proteoforms) in blood samples. If present, these biomarkers are indicative of the likely rate of mental decline for a given AD patient. This is important because such information could be used by clinicians in early diagnosis to differentiate AD patients from those with mild cognitive impairment, and also by researchers to help develop better drugs to counter this devastating disease. Research conducted by the Alzheimer's Society shows that, in 2019, there were over 850,000 people with dementia in the UK. The Society considers that more than 520,000 people in the UK have dementia caused by Alzheimer's disease and this figure is set to rise. Recent Insider Transactions • May 07
CEO & Director recently sold UK£827k worth of stock On the 5th of May, Trevor Brown sold around 1m shares on-market at roughly UK£0.57 per share. In the last 3 months, they made an even bigger sale worth UK£1.7m. Trevor has been a seller over the last 12 months, reducing personal holdings by UK£4.4m. Executive Departure • Apr 08
Independent Non-Executive Director has left the company On the 29th of March, Jonathan Freeman's tenure as Independent Non-Executive Director ended after 5.1 years in the role. As of December 2020, Jonathan personally held 344.83k shares (UK£97k worth at the time). Jonathan is the only executive to leave the company over the last 12 months. Recent Insider Transactions • Apr 02
CEO & Director recently sold UK£1.7m worth of stock On the 31st of March, Trevor Brown sold around 2m shares on-market at roughly UK£0.75 per share. This was the largest sale by an insider in the last 3 months. Trevor has been a seller over the last 12 months, reducing personal holdings by UK£3.2m. Recent Insider Transactions • Mar 06
CEO & Director recently sold UK£689k worth of stock On the 4th of March, Trevor Brown sold around 1m shares on-market at roughly UK£0.57 per share. This was the largest sale by an insider in the last 3 months. Trevor has been a seller over the last 12 months, reducing personal holdings by UK£1.6m. Is New 90 Day High Low • Feb 15
New 90-day high: UK£0.80 The company is up 92% from its price of UK£0.41 on 17 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 12% over the same period. Tillkännagivande • Jan 31
Braveheart Investment Group plc Provides Update Concerning Progress to Develop Covid-19 Test That Paraytec Limited Is Working on in Conjunction with the University of Sheffield Braveheart Investment Group plc provided update concerning progress to develop a COVID-19 test that Paraytec Limited is working on in conjunction with the University of Sheffield. Delivery of the 500 clinical samples from Sheffield Hospitals Trust were delayed due to unprecedented pressure on hospital services responding to COVID-19. However, Paraytec has reported to Braveheart that the pipeline of clinical samples is now fully operational and additional staff have been recruited to process samples for performance assessment. The Paraytec and University of Sheffield team will use these samples to set the test operational parameters so that it attains or exceeds the recommended guidelines for upper limits on false positive and negative tests set by the Medical Health Regulatory Authority. Results from this phase of clinical testing are now expected by the end of February. To minimise the effects of this delay, Paraytec has brought forward scheduled work, using isolated lab-grown virus to optimise the operational sensitivity of instrument for the detection of pre-symptomatic and early-stage symptomatic levels of virus. Paraytec's target is to detect less than 1000 virions per millilitre of sample, which would represent a market leading performance, if achieved. By re-arranging the workflows Paraytec does not believe that there will be any overall delay to the development programme. It is already clear that current vaccines are not 100% effective and the infection risk is being compounded by the emergence of new strains of the COVID-19 virus. Braveheart has been advised that the Paraytec and University of Sheffield team believes there is, and will continue to be, a significant and ongoing demand for rapid tests for the early detection of the virus, to protect communities and the world's economy. Braveheart and Paraytec remain committed to developing a test which achieves the performance parameters specified by the Medical Health Regulatory Authority and delivers a test result in five minutes. Detection tests show that Paraytec's aptamer based viral capture system completely traps target material in 300 seconds or less, confirming that its test platform is on target to deliver a test result within a five-minute timeframe, subject to successful completion of the clinical sampling tests. Recent Insider Transactions • Dec 18
CEO & Director recently sold UK£214k worth of stock On the 10th of December, Trevor Brown sold around 945k shares on-market at roughly UK£0.23 per share. This was the largest sale by an insider in the last 3 months. Trevor has been a seller over the last 12 months, reducing personal holdings by UK£898k. Reported Earnings • Dec 05
First half 2021 earnings released: EPS UK£0.013 The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£895.4k (up 258% from 1H 2020). Net income: UK£465.5k (up UK£595.7k from 1H 2020). Profit margin: 52% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has increased by 47% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Oct 27
New 90-day high: UK£0.47 The company is up 169% from its price of UK£0.17 on 29 July 2020. The British market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is down 2.0% over the same period. Is New 90 Day High Low • Oct 05
New 90-day high: UK£0.37 The company is up 160% from its price of UK£0.14 on 07 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 1.0% over the same period. Tillkännagivande • Sep 18
Braveheart Investment Group plc Update on the Pharm2farm Anti-Viral Mask Project Braveheart Investment Group, announce that Pharm 2 Farm Limited has placed an order for an automated face mask production line which is expected to be delivered in November 2020 and commissioned by the end of December 2020. The face mask production line, which is manufactured in Europe, has the capacity to produce up to five million standard or anti-viral face masks per month. 
